Abbott Laboratories News

President of Strategy and Portfolio Management of BioScience. Prior to joining Baxter Healthcare, she worked six years with Abbott Laboratories in a series of operational assignments. "Cindy brings to the company substantial business, strategic, and leadership

program. In an enforcement action filed along with the consumer fraud settlement, the attorneys general assert that Abbott Laboratories went far beyond urging physicians to prescribe Depakote for seizure disorders such as epilepsy, which is an approved use.

Laboratories is facing a battle over its Kaletra HIV medication in yet another country. The Malaysian AIDS Council earlier this month requested that the Health Ministry issue a compulsory license so that lower-cost generic versions could be imported. The move

Laboratories (“Abbott”) recently submitted a citizen petition to FDA regarding biosimilars under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”). Specifically, the citizen petition requests that FDA not accept for filing, file, approve,

of Justice ("DOJ") announced last week that it had concluded a $1.5 billion global settlement with Abbott Labs, Inc. ("Abbott"), with a $700 million criminal fine and plea, and an $800 million civil damages settlement. The cases resulted from the qui tam complaints

report provides information on the strategic split of Abbott Laboratories into two diversified companies, medical products and research-based pharmaceutical company. The report is an essential source of information on - - Analysis on the deal - Overall rationale

that include epilepsy, migraine headaches and the symptoms associated with the manic episodes of bipolar disorder, but Abbott Laboratories allegedly marketed the drug for off-label or unapproved uses such as dementia. “Not only did Abbott engage in off-label

complex drugs approved under a New Drug Application, so there's certainly an argument to be made here. I'm just not sure Abbott will be able to win. The Hatch-Waxman law, which set up the pathway for approval of generic versions of drugs approved through NDAs,

to pause. Before you think Abbott is doomed because of a reprehensible thing like this, 11 days following this settlement, Abbott Laboratories reported better-than-expected earnings as sales surged on its injectable arthritis drug, Humira. So, no tears for

as it tries to diversify its business, using the cash it accumulated by selling its core domestic drug formulations business to Abbott Laboratories of the US for $3.8 billion in 2010. The acquisition will be concluded in June. Mumbai: The Ajay Piramal-led